What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The FDA has been actively addressing the issue of compounded GLP-1 receptor agonists (like semaglutide and tirzepatide) due to concerns about their safety and efficacy. Here's a breakdown of what happened and who is still operating legally:

What Happened with the FDA and Compounded GLP-1s:

• FDA Concerns: The FDA's primary concern is that many compounded versions of GLP-1s are not using the exact same active pharmaceutical ingredient (API) as the FDA-approved drugs (e.g., Ozempic, Wegovy, Mounjaro, Zepbound). Instead, some compounding pharmacies are using different salt forms of semaglutide or tirzepatide, or even "unapproved" versions. The FDA states that these different forms have not been evaluated for safety and efficacy, and their quality and purity may be uncertain.
• "New Drug" Status: The FDA has also stated that semaglutide and tirzepatide are "new drugs" for which the FDA has approved applications. Under federal law, compounded drugs cannot contain APIs that are identical to a commercially available, FDA-approved drug. This is where the distinction between the exact approved API and different salt forms or versions becomes critical.
• Warning Letters and Actions: The FDA has issued warning letters to compounding pharmacies and other entities that were marketing or distributing these compounded GLP-1s. They have emphasized that these compounded versions may not be safe or effective and can pose significant risks to patients.
• Impact on Prescribing: While the FDA cannot ban compounding outright (it's a legal practice under specific circumstances), their strong warnings and actions have made many healthcare providers hesitant to prescribe compounded versions due to liability concerns and the lack of FDA assurance regarding their quality and safety.

Who is Still Operating Legally?

This is a nuanced question, as "legally" can depend on specific state regulations and the exact nature of the compounding. However, here are the key areas and types of operations that are generally considered to be operating within the FDA's guidelines for compounded drugs:

1. Compounding Pharmacies Using FDA-Approved APIs (but with caveats):

   • Scenario: Some compounding pharmacies legally compound drugs by using APIs that are not identical to the FDA-approved versions. This means they might be using different salt forms of semaglutide or tirzepatide that are not the specific ones used in Ozempic/Wegovy or Mounjaro/Zepbound.
   • Why it's Legal (in principle): The FDA's stance is that a compounded drug is legal if it is for an individual patient's prescription based on a valid prescriber-patient relationship, and the API is not identical to an FDA-approved drug.
   • The Gray Area: The FDA's primary concern is still the lack of safety and efficacy data for these different salt forms. While the compounding may be technically legal under federal law regarding the API identity, the FDA still strongly advises against their use due to the unknown risks. They are essentially saying, "Even if you're technically following the rules on API identity, we haven't approved these versions, and they could be unsafe."

2. Pharmacies Compounding Based on State Regulations and FDA Guidance:

   • State Pharmacy Boards: Compounding is also heavily regulated by individual state boards of pharmacy. Pharmacies must adhere to both federal and state laws.
   • The "503A" and "503B" Distinction:
     • 503A Pharmacies: These are traditional compounding pharmacies that compound medications on a patient-specific basis. They are expected to adhere to the "bulk drug substances" list and other FDA guidance.
     • 503B Facilities: These are outsourcing facilities that can compound larger batches of drugs for distribution to healthcare facilities. They have stricter FDA oversight and manufacturing standards.
   • What's Generally Considered Risky by FDA: Compounding pharmacies that are using APIs that are identical to the FDA-approved versions, or that are claiming their compounded versions are bioequivalent to the approved drugs without adequate data, are the ones drawing FDA scrutiny.

Key Takeaway for Consumers:

• The safest and most regulated path to GLP-1 medications is through FDA-approved products prescribed by your doctor. This ensures you are receiving a drug that has undergone rigorous testing for safety and efficacy.
• Be extremely cautious of compounded GLP-1s. While some may be technically "legal" to compound in certain ways, the FDA has raised significant safety and efficacy concerns about many of them. The quality, purity, and actual effectiveness of these compounded versions are often uncertain.
• Always discuss any treatment options, including compounded medications, with your doctor. They can help you understand the risks and benefits and determine the best course of action for your health.

In summary, the FDA's actions are aimed at protecting patients from potentially unsafe and ineffective compounded versions of popular weight-loss drugs. While compounding itself is legal under specific circumstances, the FDA has made it clear that many current compounded GLP-1s fall outside of their acceptable guidelines due to concerns about the APIs used and the lack of data supporting their safety and efficacy.